Does the Arbuthnot or the NatWest share price offer the best value?
So let's break down their forward valuations and dividend prospects to see which might offer better value for 2025 through 2027.
NatWest's forward price-to-earnings (P/E) ratio is expected to fall from 9.18 times in 2025 before falling back to 8.24 times in 2026 and 7.54 times in 2027. This reflects a continued earnings growth as the macroeconomic situation improves.
Arbuthnot, on the other hand, has a P/E falling from 7.37 times in 2025, then declining to 6.28 times in 2026 and 5.49 times in 2027. Arbuthnot's lower multiples suggest it's trading at a discount relative to NatWest, though its earnings are less predictable.
NatWest's dividend per share is forecast to increase from 17p in 2024 to 29p in 2025, 32p in 2026, and 36p in 2027, translating to a dividend yield rising from 5.35% to 6.84%. Its payout ratio is steady around 40-51%, indicating a balanced approach between rewarding shareholders and retaining capital.
Arbuthnot's dividends are expected to fall from 2024 — an exceptional year at 69p — falling to 53p in 2025, and then rising to 57p in 2026, and 61p in 2027, with the yield reaching 6.39% at the end of the period. Its payout ratio's expected to fall from 45% in 2024 to 35% in 2027.
NatWest's price-to-book-ratio (PBR) is forecast to rise from 0.82 times in 2024 to 1.12 times in 2025. It then eases to 0.96 times in 2027, showing growing investor confidence. Arbuthnot's PBR's lower, around 0.54 times in 2024 with no onward forecast. Both banks trade at similar enterprise value-to-revenue multiples near 0.8–0.85 times in 2025, indicating comparable market pricing relative to revenues.
NatWest benefits from a strong capital position, improving net interest margins, and a supportive UK banking environment, driving steady earnings growth. Arbuthnot, a smaller, more niche player, also shows rapid revenue growth but more earnings volatility, which may appeal to investors seeking higher risk and reward.
Arbuthnot looks slightly cheaper, based on forward earnings metrics, despite having a marginally lower dividend yield. I would however, suggest that the lower payout ratio could lead to faster dividend growth. Personally, I favour the AIM-listed bank. However, I appreciate that being AIM listed, it may be easily overlooked by investors. Coupled with its smaller size, it may continue to trade at a discount to larger peers.
I believe investors should consider both stocks, and decide which is right for their portfolios. However, my choice is Arbuthnot, and I've recently opened a small position in the bank.
The post Does the Arbuthnot or the NatWest share price offer the best value? appeared first on The Motley Fool UK.
More reading
5 Stocks For Trying To Build Wealth After 50
One Top Growth Stock from the Motley Fool
James Fox has no position in Arbuthnot Banking Group PLC. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
Motley Fool UK 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today
Key Points Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P 500 index fund. Still, Pfizer today offers a fat dividend and plenty of growth potential. 10 stocks we like better than Pfizer › Wondering how well you'd have done if you'd invested in pharmaceutical giant Pfizer (NYSE: PFE) three years ago and hung on? Well, I'm afraid the answer isn't pretty: If you'd investing $1,000 in Pfizer on Aug. 8, 2022, hung on and reinvested dividends, that sum would have been worth $585 on Aug. 8, 2025. Ouch! For some context, during those same three years, the S&P 500 index of 500 of America's biggest companies averaged gains of roughly 17% per year, turning $1,000 into $1,615. Here's some good news, though: Stock investors need to look forward much more than backward. Trailing returns are in the past. What matters most for current Pfizer investors and would-be Pfizer investors is how the company will perform from here on. And Pfizer's future is looking promising. Some investors have been disappointed in Pfizer when they've compared recent results to those from the past. But those past years were exceptional boom years thanks to Pfizer's COVID-19 vaccine and Paxlovid COVID-19 treatment. Those were in great demand, but demand has fallen. Others worry because some of Pfizer's big sellers, such as Eliquis, Ibrance, Inlyta, Xeljanz, Xtandi, and Vyndaqel, are coming off patent protection in the next few years. Pfizer has been planning for that, and investing in its pipeline, which features more than 100 active programs -- many of which are in oncology. Pfizer has also been getting additional approvals for its drugs, and it has been cutting its costs in an effort to boost profitability. Finally, Pfizer is a dividend-paying stock, with a whopping recent dividend yield of 7%. So as you invest in Pfizer and wait for its investments to pay off, you'll be rewarded. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Selena Maranjian has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Yahoo
14 minutes ago
- Yahoo
Nium and iPiD Deepen Strategic Collaboration to Advance VoP Compliance and Global Fraud Prevention
SINGAPORE, Aug. 11, 2025 /PRNewswire/ -- Nium, the leading global infrastructure for real-time cross-border payments, today announced the expansion of Verify, its account validation service, in Europe, through a strengthened strategic partnership with iPiD, the provider of the Know Your Payee (KYP) solution, iPiD Node. As part of this deepening collaboration, iPiD is also leveraging Nium's Verify technology to enhance its own validation capabilities, marking a mutual partnership between two of Singapore's most prominent fintech innovators. By tapping into Nium's established account verification infrastructure, iPiD is able to enhance its global coverage. This two-way partnership underscores both companies' shared vision to increase trust, reduce fraud, and meet evolving regulatory demands in cross-border payments. With VoP becoming a regulatory requirement in the EU by October 2025, payment service providers (PSPs) will be expected not only to verify payee details but also to demonstrate that verification was attempted and properly recorded. Through this collaboration, the integration of iPiD Node extends the reach of Nium's Verify solution in the EU, with audit-ready coverage in the additional 41 countries of the SEPA zone; adding to Nium's instant account verification capabilities in 25 countries globally. Nium's position as the only provider with direct access to global RTP schemes for the purpose of both payments and real-time account validation is complemented by iPiD Node's compliance-ready infrastructure. Since Nium launched Verify, it has helped customers save millions of dollars in fraud and error related costs. A leading global remittance provider saw their error rates reduce from 1.41% to 0.34% after implementing Verify. At the same time, iPiD Node has enabled institutions to meet increasingly stringent VoP compliance requirements through evidence-ready audit logs, while helping reduce false positives and manual reviews in high-risk cross-border transactions. "It's powerful when a trusted partner chooses to become a customer," said Damien Dugauquier, Co-founder & CEO at iPiD. "We're proud to work alongside Nium — not just as fellow Singapore fintechs, but as like-minded teams solving the next generation of cross-border compliance and fraud challenges." While many providers rely solely on name-matching tools for payee validation, Nium's Verify solution, with the integration of the iPiD Node allows its infrastructure to deliver an elevated experience, leveraging real-time API responses directly from domestic RTP systems for unmatched accuracy and fraud prevention, while also providing transparent, accurate and secure cross-border transactions. The addition of iPiD Node also ensures advanced capabilities in the EU including: Real-time request/response name-checking flows Evidence-ready forensics and audit logs to meet regulatory requirements Flexible name-matching logic to balance security with usability "As regulation and risk evolve, we're focused on building infrastructure that goes beyond the payment to provide both compliant and customer-centric solutions," said Alexandra Johnson, Chief Payments Officer at Nium. "Deepening our relationship with iPiD gives us the tools to further scale our Verify solution for account validation with confidence." The collaboration also reflects growing synergy between Singapore's fintech leaders in advancing secure, compliant, and scalable financial infrastructure on the global stage. Together, Nium and iPiD are setting a new standard for payee verification - combining real-time intelligence, regulatory readiness, and ecosystem collaboration to make global payments safer and smarter. About Nium Nium, the leading global infrastructure for real-time cross-border payments, was founded on the mission to deliver the global payments infrastructure of tomorrow, today. With the onset of the global economy, its payments infrastructure is shaping how banks, fintechs, and businesses everywhere collect, convert, and disburse funds instantly across borders. Its payout network supports 100 currencies and spans 190+ countries, 100 of which in real-time. Funds can be disbursed to accounts, wallets, and cards and collected locally in 40 markets. Nium's growing card issuance business is already available in 34 countries. Nium holds regulatory licenses and authorizations in more than 40 countries, enabling seamless onboarding, rapid integration, and compliance – independent of geography. The company is co-headquartered in San Francisco and Singapore. About iPiDiPiD is a global leader in Know Your Payee (KYP) solutions, specializing in payee verification. Our technology enables financial institutions, payments service providers and corporations to improve payment experiences, reduce errors, protect against fraud and ensure compliance. Logo - View original content to download multimedia: SOURCE Nium
Yahoo
37 minutes ago
- Yahoo
One bed flats planned for one of town's oldest buildings
A SECTION of one of Shipley's oldest buildings could be converted into one bed flats if new plans are approved. The town's Conservative Club, also known as Shipley Old Hall, dates back to the 17th Century, and is Grade II listed. Now the Otley Road hall is the subject of a planning application to change the use of part of the building to residential, and to install new UPVC windows in the centuries old property. Located near the entrance to Shipley Rail Station, the building was recently sold and the new application to convert the property into residential use has been submitted by Majid Ali. The application says the work will 'improve an area that is currently in a derelict and unused state.' Painted windows at the former Shipley Conservative Club building (Image: T&A) The plans would see a section of the building, including its more modern extension, converted into five one bed flats spread out over two floors. Render on the more modern extension to the building would be covered with timber cladding. A more modern section of the former Conservative Club building (Image: T&A) Timber framed windows/doors would be replaced by UPVC framed double glazed units and composite doorsets. Five of the 30 parking spaces on the site would be allocated to the flats, including two EV spaces. The application says: 'At present the subject site is vacant and recently purchased by the applicant who would like to carry out refurbishment works including improvements and change of use to part of the property into flats. 'The applicant purchased this site for development purposes including bringing this Grade II Listed Building back into use that is subject to planning and conservation area consent. "The site is not currently in use and in need of refurbishment and is considered as being in a prime location for the conversion and development programme that is subject to gaining the relevant permission. 'No external alterations are proposed apart from the replacement of windows and doors that are in urgent need of upgrading due to their deteriorating condition and also to meet the current building regulations. 'The proposed change of use is aimed at preserving and making use of this historic property to provide a positive contribution to the area as a whole. The proposal will provide employment opportunities to support the local economy directly and indirectly. 'The proposal will improve the site area that is currently in a derelict and unused state.' A decision on the application is expected in October.
